SAN DIEGO, Dec. 4, 2012 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, today announced that the Company will provide details of obesity therapeutics market research including the results of surveys of 1,000 physicians and 6,000 patients during an Analyst Day event on December 18, 2012. The Company will also provide an update to the Contrave® Light Study and discuss U.S. and EU regulatory planning.
The Analyst Day event will be held in New York City on December 18, 2012 from 9 a.m. to 12 p.m. Eastern Time.
While attendance in person is by invitation only, Orexigen will webcast the Analyst Day presentations. The webcast can be accessed live on the Investor Relations section of the Orexigen website at www.orexigen.com and will be archived for 14 days following the call.
About Orexigen Therapeutics Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead product candidate is Contrave®, which has completed Phase III clinical trials and for which a New Drug Application has been submitted and reviewed by the FDA. The Company has also reached agreement with the FDA on a Special Protocol Assessment (SPA) for the Light Study, the Contrave cardiovascular outcomes trial. The Company's other product candidate, Empatic™, has completed Phase II clinical trials. Further information about the Company can be found at www.orexigen.com.
Source: Orexigen Therapeutics McDavid Stilwell Vice President, Corporate Communications & Business Development 858-875-8600
SOURCE Orexigen Therapeutics, Inc.